Article
[Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics].
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Dec 2025
Liang Guowei, Wu Hongfeng, Jia Chaoyi, Gao Penghu, Zhang Zhanrui, Chen Chen, Li Yongwen, Liu Hongyu, Chen Jun
Abstract excerpt
BACKGROUND: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC), and epidermal growth factor receptor (EGFR) mutation is its primary molecular driver event. Although the third-generation tyrosine kinase inhibitors (TKIs) Osimertinib has become the standard first-line therapy for such patients, the development of drug resistance severely limits long-term survival benefits....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.